Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

被引：0

作者：

Daisuke Minakata

Tadao Ishida

Kiyoshi Ando

Rikio Suzuki

Junji Tanaka

Shotaro Hagiwara

Revathi Ananthakrishnan

Shigeki Kuwayama

Mitsufumi Nishio

Yoshinobu Kanda

Kenshi Suzuki

机构：

[1] Jichi Medical University,Division of Hematology, Department of Medicine

[2] Japanese Red Cross Medical Center,Department of Hematology

[3] Tokai University School of Medicine,Department of Hematology and Oncology

[4] Tokyo Women’s Medical University,Department of Hematology

[5] University of Tsukuba,Faculty of Medicine

[6] Bristol Myers Squibb,undefined

[7] Bristol Myers Squibb K.K,undefined

来源：

International Journal of Hematology | 2023年 / 117卷

关键词：

Relapsed/refractory multiple myeloma; CAR T cell therapy; Japanese patients; Idecabtagene-vicleucel; Triple-class exposed;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：729 / 737

页数：8

共 50 条

[21] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Einsele, Hermann
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus
Munshi, Nikhil C.
Oriol, Albert
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
[22] Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial
Ayers, Dieter
Cope, Shannon
Dhanda, Devender S.
Towle, Kevin
Mojebi, Ali
Delforge, Michel
Rodriguez-Otero, Paula
Trudel, Suzanne
Weisel, Katja
Zamagni, Elena
Hari, Parameswaran
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S139 - S140
[23] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
Munshi, Nikhil C.
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur S.
Siegel, David Samuel DiCapua
Lin, Yi
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Petrocca, Fabio
Connarn, Jamie
Patel, Payal
Huang, Liping
Campbell, Timothy Brandon
Hege, Kristen
San Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL
Hari, P.
Nguyen, A.
Pelletier, C.
Hege, K.
McGarvey, N.
Gitlin, M.
Parikh, K.
VALUE IN HEALTH, 2021, 24 : S29 - S30
[25] Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor plus dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
Rodriguez-Otero, Paula
Ayers, Dieter
Cope, Shannon
Davies, Faith E.
Delforge, Michel
Mojebi, Ali
Jansen, Jeroen P.
Weisel, Katja
Hege, Kristen
Dhanasiri, Sujith
LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2482 - 2491
[26] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna E.
Rambaldi, Alessandro
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S18
[27] KARMMA STUDY: CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH MULTIPLE RELAPSE/REFRACTORY MYELOMA (MMRR) TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
Albert, Oriol
Ankit, Kansagra
Yi, Lin
Jesus, Berdeja
Nina, Shah
Ibrahim, Yakoub-Agha
Hermann, Einsele
Alessandro, Rambaldi
Anna, Truppel-Hartmann
Everton, Rowe
Julie, Wang
Amit, Agarwal
Timothy, Campbell B.
Sagar, Lonial
HAEMATOLOGICA, 2021, 106 (10) : 77 - 78
[28] Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
Lin, Yi
Raje, Noopur S.
Berdeja, Jesus G.
Siegel, David S.
Jagannath, Sundar
Madduri, Deepu
Liedtke, Michaela
Rosenblatt, Jacalyn
Maus, Marcela V.
Massaro, Monica
Petrocca, Fabio
Caia, Andrea
Yang, Zhihong
Campbell, Timothy B.
Hege, Kristen
Munshi, Nikhil C.
Kochenderfer, James N.
BLOOD, 2020, 136
[29] Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
McGarvey, November
Ung, Brian
Carattini, Thomas
Campbell, Timothy
Lee, Abraham
Patwardhan, Pallavi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S181
[30] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A CAR T THERAPY TARGETING BCMA, IN PATIENTS WITH MULTIPLE RECLAIMER/REFRACTORY MYELOMA (MMRR): UPDATE FROM THE KarMMa STUDY
Albert, Oriol
Jesus, San-Miguel
Ankit, Kansagra
Deepu, Madduri
Nina, Shah
Philippe, Moreau
Ibrahim, Yakoub-Agha
Michel, Delforge
Michele, Cavo
Hermann, Einsele
Hartmut, Goldschmidt
Katja, Weisel
Alessandro, Rambaldi
Donna, Reece
Paula, Rodriguez-Otero
Fabio, Petrocca
Jamie, Connarn N.
Payal, Patel
Huang Liping
Timothy, Campbell B.
Kristen, Hege
Nikhil, Munshi C.
HAEMATOLOGICA, 2021, 106 (10) : 76 - 77

← 1 2 3 4 5 →